Literature DB >> 28454343

Promoter hypermethylation of the RECK gene is associated with its low expression and poor survival of esophageal squamous cell carcinoma.

Jing Zhu1, Yang Ling1, Yun Xu2, Mingzhu Lu1, Yongping Liu1, Changsong Zhang1.   

Abstract

The present study aimed to investigate the association between the methylation status of the reversion-inducing cysteine-rich protein with kazal motifs (RECK) gene and its mRNA expression levels in patients with esophageal squamous cell carcinoma (ESCC). The methylation status of RECK was analyzed by methylation-specific polymerase chain reaction (PCR), and RECK mRNA expression levels were analyzed by quantitative PCR, in 310 paired ESCC tissues. The mean RECK methylation index (MI) was 0.65 in ESCCs and 0.49 in non-tumor samples. There was a significant association between RECK methylation and the American Joint Committee on Cancer stage and lymph node metastasis in ESCC (P<0.0001; P=0.001). The mRNA expression level of RECK was lower in ESCC tissues (mean-∆Cq=-4.66) compared with non-tumor tissues (mean-∆Cq=-2.79), and decreased RECK mRNA expression levels were associated with lymph node metastasis in ESCC. In addition, RECK mRNA levels were decreased in ESCC patients with hypermethylation of the RECK gene (∆MI >0.16; mean-∆∆Cq=-2.85) compared with those with hypomethylation of the RECK gene (∆MI ≤0.16; mean-∆∆Ct=-0.83), and there was a significant difference in the mRNA expression levels of RECK between those with N0-1 and N2-3 lymph node metastasis (P<0.0001). A significant correlation was observed between RECK mRNA expression levels, the MI of RECK and poor postoperative survival (P=0.0003; P<0.0001). The results of the present study suggested that promoter hypermethylation may be an important factor for loss of RECK mRNA expression and may be an indicator of poor survival in ESCC.

Entities:  

Keywords:  esophageal squamous cell carcinoma; methylation; reversion-inducing cysteine-rich protein with kazal motifs

Year:  2017        PMID: 28454343      PMCID: PMC5403254          DOI: 10.3892/ol.2017.5656

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  31 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Esophageal squamous cell carcinoma with special reference to its early stage.

Authors:  Michio Shimizu; Giovanni Zaninotto; Koji Nagata; David Y Graham; Gregory Y Lauwers
Journal:  Best Pract Res Clin Gastroenterol       Date:  2013-04       Impact factor: 3.043

3.  Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma.

Authors:  Changsong Zhang; Yun Xu; Jun Zhao; Lieying Fan; Guocheng Jiang; Rong Li; Yang Ling; Mengchao Wu; Lixin Wei
Journal:  Ann Surg Oncol       Date:  2011-02-18       Impact factor: 5.344

4.  Downregulation of RECK by promoter methylation correlates with lymph node metastasis in non-small cell lung cancer.

Authors:  Huang-Chou Chang; Chun-Yu Cho; Wen-Chun Hung
Journal:  Cancer Sci       Date:  2007-02       Impact factor: 6.716

Review 5.  RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer.

Authors:  Jonathan C M Clark; David M Thomas; Peter F M Choong; Crispin R Dass
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

6.  Oesophageal squamous cell carcinoma in high-risk Chinese populations: Possible role for vascular epithelial growth factor A.

Authors:  Asieh Golozar; Terri H Beaty; Patti E Gravitt; Ingo Ruczinski; You-Lin Qiao; Jin-Hu Fan; Ti Ding; Ze-Zhong Tang; Arash Etemadi; Nan Hu; Paula L Hyland; Lemin Wang; Chaoyu Wang; Sanford M Dawsey; Neal D Freedman; Christian C Abnet; Alisa M Goldstein; Philip R Taylor
Journal:  Eur J Cancer       Date:  2014-08-26       Impact factor: 9.162

Review 7.  The RECK gene and biological malignancy--its significance in angiogenesis and inhibition of matrix metalloproteinases.

Authors:  Michelle Alexius-Lindgren; Erika Andersson; Ingrid Lindstedt; Wilhelm Engström
Journal:  Anticancer Res       Date:  2014-08       Impact factor: 2.480

8.  Significance of methylation status and the expression of RECK mRNA in lung tissue of patients with NSCLC.

Authors:  M Pesta; V Kulda; O Topolcan; J Safranek; J Vrzalova; R Cerny; L Holubec
Journal:  Anticancer Res       Date:  2009-11       Impact factor: 2.480

9.  Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral squamous cell carcinoma cells.

Authors:  K Kato; N K Long; H Makita; M Toida; T Yamashita; D Hatakeyama; A Hara; H Mori; T Shibata
Journal:  Br J Cancer       Date:  2008-07-29       Impact factor: 7.640

10.  E-cadherin-downregulation and RECK-upregulation are coupled in the non-malignant epithelial cell line MCF10A but not in multiple carcinoma-derived cell lines.

Authors:  Kanako Yuki; Yoko Yoshida; Ryosaku Inagaki; Hiroshi Hiai; Makoto Noda
Journal:  Sci Rep       Date:  2014-04-02       Impact factor: 4.379

View more
  3 in total

1.  Identification of potential genes in upper tract urothelial carcinoma using next-generation sequencing with bioinformatics and in vitro analyses.

Authors:  Hsiang-Ying Lee; Ching-Chia Li; Wei-Ming Li; Ya-Ling Hsu; Hsin-Chih Yeh; Hung-Lung Ke; Bi Wen Yeh; Chun-Nung Huang; Chien-Feng Li; Po-Lin Kuo; Wen-Jeng Wu
Journal:  PeerJ       Date:  2021-04-27       Impact factor: 2.984

2.  Integrated Analysis of Transcriptomic and Genomic Data Reveals Blood Biomarkers With Diagnostic and Prognostic Potential in Non-small Cell Lung Cancer.

Authors:  Ibrahim H Kaya; Olfat Al-Harazi; Mustafa T Kaya; Dilek Colak
Journal:  Front Mol Biosci       Date:  2022-03-04

Review 3.  Multifaceted Roles of DNA Methylation in Neoplastic Transformation, from Tumor Suppressors to EMT and Metastasis.

Authors:  Laura Casalino; Pasquale Verde
Journal:  Genes (Basel)       Date:  2020-08-12       Impact factor: 4.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.